Sclerostin Expression and Functions Beyond the Osteocyte

Overview

Journal Bone

Specialties Endocrinology
Orthopedics

Date 2016 Nov 27

PMID 27888056

Citations 76

Authors

Megan M Weivoda

Stephanie J Youssef

Merry Jo Oursler

Affiliations

Soon will be listed here.

Abstract

Sclerostin, the product of the SOST gene, is a secreted inhibitor of Wnt signaling that is produced by osteocytes to regulate bone formation. While it is often considered an osteocyte-specific protein, SOST expression has been reported in numerous other cell types, including hypertrophic chondrocytes and cementocytes. Of interest, SOST/sclerostin expression is altered in certain pathogenic conditions, including osteoarthritis and rheumatic joint disease, and it is unclear whether sclerostin plays a protective role or whether sclerostin may mediate disease pathogenesis. Therefore, as anti-sclerostin antibodies are being developed for the treatment of osteoporosis, it is important to understand the functions of sclerostin beyond the regulation of bone formation.

Citing Articles

Low Bone Turnover, Mineralization Impairment, and Cortical Alterations in Patients with Axial Spondyloarthritis: A Histomorphometric Study.

Machado N, Pinheiro M, Chula D, Ceron R, Pinheiro F, Serrato V Calcif Tissue Int. 2025; 116(1):17.

PMID: 39751834 DOI: 10.1007/s00223-024-01314-0.

Osteokines in Nonalcoholic Fatty Liver Disease.

Vachliotis I, Anastasilakis A, Rafailidis V, Polyzos S Curr Obes Rep. 2024; 13(4):703-723.

PMID: 39225951 DOI: 10.1007/s13679-024-00586-9.

Bone proteins are associated with cardiovascular risk according to the SCORE2-Diabetes algorithm.

Gonzalez-Salvatierra S, Garcia-Martin A, Garcia-Fontana B, Martinez-Heredia L, Garcia-Fontana C, Munoz-Torres M Cardiovasc Diabetol. 2024; 23(1):311.

PMID: 39182106 PMC: 11344922. DOI: 10.1186/s12933-024-02406-9.

Disparate effects of sclerostin deletion on alveolar bone and cellular cementum in mice.

Phanrungsuwan A, Chavez M, Eltilib L, Kolli T, Mohamed F, Tan M J Periodontol. 2024; 96(1):82-96.

PMID: 39012429 PMC: 11735692. DOI: 10.1002/JPER.24-0025.

Fatty infiltration in the musculoskeletal system: pathological mechanisms and clinical implications.

Zhu Y, Hu Y, Pan Y, Li M, Niu Y, Zhang T Front Endocrinol (Lausanne). 2024; 15:1406046.

PMID: 39006365 PMC: 11241459. DOI: 10.3389/fendo.2024.1406046.

References

Gonzalez-Reimers E, Martin-Gonzalez C, de la Vega-Prieto M, Pelazas-Gonzalez R, Fernandez-Rodriguez C, Lopez-Prieto J . Serum sclerostin in alcoholics: a pilot study. Alcohol Alcohol. 2013; 48(3):278-82. DOI: 10.1093/alcalc/ags136. View

Velasco J, Zarrabeitia M, Prieto J, Perez-Castrillon J, Perez-Aguilar M, Perez-Nunez M . Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study. Osteoporos Int. 2009; 21(1):109-18. DOI: 10.1007/s00198-009-0931-0. View

Sevetson B, Taylor S, Pan Y . Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem. 2004; 279(14):13849-58. DOI: 10.1074/jbc.M306249200. View

Sakellariou G, Anastasilakis A, Bisbinas I, Oikonomou D, Gerou S, Polyzos S . Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. Rheumatology (Oxford). 2014; 54(5):908-14. DOI: 10.1093/rheumatology/keu425. View

Chan B, Fuller E, Russell A, Smith S, Smith M, Jackson M . Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage. 2011; 19(7):874-85. DOI: 10.1016/j.joca.2011.04.014. View

van Bezooijen R, DeRuiter M, Vilain N, Monteiro R, Visser A, van der Wee-Pals L . SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Dev Dyn. 2006; 236(2):606-12. DOI: 10.1002/dvdy.21054. View

Yavropoulou M, van Lierop A, Hamdy N, Rizzoli R, Papapoulos S . Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone. 2012; 51(1):153-7. DOI: 10.1016/j.bone.2012.04.016. View

Ominsky M, Li C, Li X, Tan H, Lee E, Barrero M . Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011; 26(5):1012-21. DOI: 10.1002/jbmr.307. View

Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B . A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016; 7:11505. PMC: 4894982. DOI: 10.1038/ncomms11505. View

10.

Jager A, Gotz W, Lossdorfer S, Rath-Deschner B . Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J Periodontal Res. 2009; 45(2):246-54. DOI: 10.1111/j.1600-0765.2009.01227.x. View

11.

Brunkow M, Gardner J, Van Ness J, Paeper B, Kovacevich B, Proll S . Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68(3):577-89. PMC: 1274471. DOI: 10.1086/318811. View

12.

Zhao N, Nociti Jr F, Duan P, Prideaux M, Zhao H, Foster B . Isolation and Functional Analysis of an Immortalized Murine Cementocyte Cell Line, IDG-CM6. J Bone Miner Res. 2015; 31(2):430-442. PMC: 4827449. DOI: 10.1002/jbmr.2690. View

13.

Chen X, Baum W, Dwyer D, Stock M, Schwabe K, Ke H . Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis. 2013; 72(10):1732-6. PMC: 3786639. DOI: 10.1136/annrheumdis-2013-203345. View

14.

Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C . Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Miner Res. 2008; 24(1):12-21. PMC: 2640321. DOI: 10.1359/jbmr.080901. View

15.

Staehling-Hampton K, Proll S, Paeper B, Zhao L, Charmley P, Brown A . A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110(2):144-52. DOI: 10.1002/ajmg.10401. View

16.

Power J, Poole K, Van Bezooijen R, Doube M, Caballero-Alias A, Lowik C . Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture. J Bone Miner Res. 2010; 25(8):1867-76. DOI: 10.1002/jbmr.70. View

17.

Radin E, Rose R . Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res. 1986; (213):34-40. View

18.

Mabey T, Honsawek S, Tanavalee A, Wilairatana V, Yuktanandana P, Saetan N . Plasma and synovial fluid sclerostin are inversely associated with radiographic severity of knee osteoarthritis. Clin Biochem. 2014; 47(7-8):547-51. DOI: 10.1016/j.clinbiochem.2014.03.011. View

19.

Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A . Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem. 2003; 278(26):24113-7. DOI: 10.1074/jbc.M301716200. View

20.

Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E . Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. J Clin Endocrinol Metab. 2015; 100(12):4669-76. DOI: 10.1210/jc.2015-3056. View